A5314: Effect of LDMTX on Inflammation in HIV-infected Individuals

Study Location:

Baltimore

Topic:

HIVCardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT01949116?term=a5314&rank=2

IRB#:

NA_00088694

Coordinator:

Ilene Wiggins, RN

Enrollment:

Closed

Trial Period:

Completed

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of LDMTX on endothelial function and inflammation in virologically suppressed HIV-infected participants.

HIV-infected men and women ≥40 years old, who have been virologically suppressed on continuous antiretroviral therapy for at least 24 weeks; who have a CD4+ T-cell count ≥400 cells/mm3; and who have documented CVD or who are at increased CVD risk.

410-955-2898

Categories

Location
Topic

Clinical Trials

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More